# Malignancy Meta Analysis for BRL49653

> **NCT01195259** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** allocation of treatment with metformin or rosiglitazone

## Key facts

- **NCT ID:** NCT01195259
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2013-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01195259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01195259, "Malignancy Meta Analysis for BRL49653". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01195259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*